Year-End Sale is Live! Find Exclusive Prices on the Best Selling Pharma & MedTech Reports. Check Now!
Oct 30, 2024
Neuroendocrine tumors are a complex group of tumors that develop predominantly in the digestive or respiratory tract but can occur in many areas of the body. These tumors arise from cells called neuroendocrine cells. Like all cancers, NETs develop when the specialized cells undergo changes, causing them to divide u...
Read More...
Jun 02, 2022
GenScript USA Announced the Distribution Agreement with EUROIMMUN US for cPass SARS-CoV-2 Neutralizing Antibody Detection Kit On May 26, 2022, GenScript USA Inc., a subsidiary of GenScript Biotech Corporation and a world-leading biotechnology company, agreed with EUROIMMUN US Inc., a PerkinElmer Company, for the...
Read More...
Feb 01, 2022
Immunocore Receives FDA Approval for the First Uveal Melanoma Treatment, As Well As the First T-cell Receptor Therapeutics Uveal Melanoma, an aggressive eye cancer, has proven to be a tough nut to crack for researchers seeking a cure. However, with the approval of a new treatment, those with the disorder will ha...
Read More...
Aug 18, 2020
New strategy, new outlook: Sanofi takes another step, gains full control over the Principia’s MS treatment Sanofi has inked a definitive agreement with Principia Biopharma to acquire the company, all of its outstanding shares, and its BTK inhibitors in a deal worth USD 3.68 Billion. The deal is expected t...
Read More...
Dec 19, 2017
Regeneron/Sanofi’s PD-1 drug candidate will be tested with ISA’s HPV immunotherapy Regeneron and Sanofi’s PD-1 candidate cemiplimab is paired with Dutch biotech ISA Pharma’s human papillomavirus (HPV) targeting drug for testing. The new drug is competing to become the sixth PD-1/PD-L1 drug on the market. Joined with...
Read More...
Apr 19, 2017
Loss of VHL and elevated expression of HIF transcription factors leads to reprogramming of tumour cell metabolism, enabling renal cell carcinoma (RCC) cells to use carbons from glutamine-derived aspartate to drive pyrimidine biosynthesis. Now, researchers show that inhibition of glutamine availability decreases aspa...
Read More...
Sep 28, 2016
Merck is a leading science and technology company, and has many projects that are involved in research to find treatments for diseases that are hard to treat. Keeping in view with this agenda, Merck has announced that the new research that has been conducted from their marketed and pipeline compounds will be present...
Read More...
Roche’s HER2-Positive Breast Cancer Treatment Franchise
Aug 13, 2024
Transforming Multiple Myeloma Treatment: The Promise of Novel Drug Classes
Jul 24, 2024
Newsletter/Whitepaper